Product Overview

Introducing the first and only point-of-care tests for early detection of type-1 diabetes and LADA

(Latent Autoimmune Diabetes in Adults)

Three Tests for Three Autoantibodies:

Insulin Autoantibodies to insulin (IAA) can predict risk of type-1 diabetes or confirm a diagnosis of type-1 diabetes. IAA are most common in children with or at risk for type-1 diabetes.

GAD, GAD65 Autoantibodies to GAD (GADA), like IAA, are also predictive of risk for type-1 diabetes. GAD autoantibodies are present in the majority of adult patients with autoimmune diabetes.

IA-2 Autoantibodies against IA-2 (IA2-A) are the second most common autoantibody in type-1 diabetes. GAD and IA-2 autoantibodies are the most common in type-2 diabetes that also has an autoimmune component.

For children,the number of autoantibodies present is a better predictor of disease risk than the presence of any single antibody.

Who Should Be Tested

√ Children with suspected classical type-1 diabetes and their siblings.

√ Children or adolescents who present with putative type-2 diabetes, but who may, in fact, have type-1 diabetes. These patients are a distinct group that is not distinguishable without autoantibody screening, and may benefit from different interventions.

√ Adults suspected of having type-1 diabetes, since a significant proportion of type-1 diabetes patients are diagnosed as adults.

√ Patients with established or pre (type-2) diabetes in which the presence of autoantibodies in addition to insulin resistance may predict a more rapid progression to insulin deficiency.

√ Diabetes patients who may have developing or established autoimmune complications such as celiac disease or autoimmune thyroid disease.

√ Pregnant women with putative gestational diabetes who may have undiagnosed type-1 diabetes.